Cellomics has announced that Serono Pharmaceutical Research has invested in high content screening (HCS) technologies with the acquisition of a Cellomics ArrayScanT HCS system
The ArrayScanT HCS system, a proprietary system developed by Cellomics, performs automated acquisition, analysis, and presentation of information on multiple spatial and temporal events in individual cells.
The ArrayScanT HCS System was developed to provide reliable insight into the efficacy and toxicity of drug candidates.
Measurement of these complex cellular responses provides researchers with additional knowledge that can be critical to accurately determine which targets to investigate and which lead compounds to pursue.
On the new acquisition, Anthony Nichols, SPRI cellular pharmacology group leader commented "The ArrayScanT HCS System will enable us to increase our efficiency, accuracy and output of cell based biological tests for small molecule and therapeutic protein discovery projects." Colleague Tim Wells, VP for discovery R&D at Serono, added "This system will play an important part of our strategy for finding new therapeutic proteins from the human genome".
Serono has six recombinant products on the market, Gonal-F, Luveris, Ovidrel/Ovitrelle, Rebif, Serostim and Saizen (Rebif and Luveris are not currently approved in the USA).
